SARS-CoV-2: Difference between revisions

From IDWiki
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations")
No edit summary
Line 1: Line 1:
== Background ==
+
==Background==
=== Microbiology ===
+
===Microbiology===
* Coronavirus related to [[SARS-CoV]]
 
   
 
*Coronavirus related to [[SARS-CoV]]
=== Epidemiology ===
 
  +
*Virion consists of:
* First cases detected Dec 2019 related to likely exposure in wet market in Wuhan, Hubei, China
 
  +
**Spike glycoprotein (S)
* Declared pandemic by WHO in 2020
 
  +
**Membrane protein (M)
  +
**Nucleocapsid protein (N)
  +
**Hemagglutinin esterase (He)
  +
**Envelope protein (E)
   
 
===Epidemiology===
== Clinical Manifestations ==
 
* Incubation period 4-5 days on average, possibly as long as 14 days in some cases
 
* Main presenting symptoms were fever and cough
 
* Other symptoms include dyspnea, rhinorrhea, vomiting, diarrhea
 
   
 
*First cases detected Dec 2019 related to likely exposure in wet market in Wuhan, Hubei, China, and declared a pandemic in 2020
== Management ==
 
  +
*Secondary household attack rate of 12-17%
* Primarily supportive
 
  +
* Investigational therapeutics include [[tocilizumab]], [[lopinavir/ritonavir]], and [[chloroquine]]
 
  +
=== Risk Factors for Mortality ===
  +
  +
* Greater age
  +
* Male sex
  +
* [[COPD]]
  +
* [[Dyslipidemia]]
  +
* [[Diabetes]]
  +
 
==Clinical Manifestations==
  +
 
*Incubation period 4-5 days (range 2 to 11), possibly as long as 14 days in some cases
 
*Main presenting symptoms were fever and cough, followed by myalgia, fatigue, headache, dyspnea
 
*Other symptoms include dyspnea, rhinorrhea, vomiting, diarrhea, anosmia/hyposmia
  +
*Lymphopenia is common, as is hypoalbuminemia, elevated D-dimer, CRP, LDH, AST/ALT
  +
*Viral load detectable before symptom onset and peaks around the time of symptom onset
  +
  +
=== Complications ===
  +
  +
* In critically ill patients:
  +
** [[ARDS]] (75%)
  +
** [[AKI]] (40%)
  +
** [[Thrombosis]] (10%)
  +
  +
== Diagnosis ==
  +
  +
* PCR from NP swab
  +
** May be positive long after no longer infectious
  +
 
==Management==
  +
  +
*Dexamethasone for patients requiring supplemental oxygen
 
*Investigational therapeutics include [[tocilizumab]], [[lopinavir/ritonavir]], and [[chloroquine]]
  +
  +
== Further Reading ==
  +
  +
* 10.1001/jama.2020.12839
   
 
[[Category:Viruses]]
 
[[Category:Viruses]]

Revision as of 19:16, 30 July 2020

Background

Microbiology

  • Coronavirus related to SARS-CoV
  • Virion consists of:
    • Spike glycoprotein (S)
    • Membrane protein (M)
    • Nucleocapsid protein (N)
    • Hemagglutinin esterase (He)
    • Envelope protein (E)

Epidemiology

  • First cases detected Dec 2019 related to likely exposure in wet market in Wuhan, Hubei, China, and declared a pandemic in 2020
  • Secondary household attack rate of 12-17%

Risk Factors for Mortality

Clinical Manifestations

  • Incubation period 4-5 days (range 2 to 11), possibly as long as 14 days in some cases
  • Main presenting symptoms were fever and cough, followed by myalgia, fatigue, headache, dyspnea
  • Other symptoms include dyspnea, rhinorrhea, vomiting, diarrhea, anosmia/hyposmia
  • Lymphopenia is common, as is hypoalbuminemia, elevated D-dimer, CRP, LDH, AST/ALT
  • Viral load detectable before symptom onset and peaks around the time of symptom onset

Complications

Diagnosis

  • PCR from NP swab
    • May be positive long after no longer infectious

Management

Further Reading

  • 10.1001/jama.2020.12839

References

  1. ^  Louise Lansbury, Benjamin Lim, Vadsala Baskaran, Wei Shen Lim. Co-infections in people with COVID-19: a systematic review and meta-analysis. Journal of Infection. 2020;81(2):266-275. doi:10.1016/j.jinf.2020.05.046.